Study: NCT01309932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (NS3 Protease Inhibitor)
Description: Tablets, Oral, 200 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (NS3 Protease Inhibitor)
Description: Tablets, Oral, 200 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (NS3 Protease Inhibitor)
Description: Tablets, Oral, 200 mg, Twice daily, 24 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon Alfa-2a (pegIFNα-2a)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda (pegIFNλ)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda (pegIFNλ)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda (pegIFNλ)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda (pegIFNλ)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Inhibitor)
Description: Tablets, Oral, 60 mg, Once daily, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Inhibitor)
Description: Tablets, Oral, 60 mg, Once daily, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (NS3 Protease Inhibitor)
Description: Tablets, Oral, 200 mg, Twice daily, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032 (NS3 Protease Inhibitor)
Description: Tablets, Oral, 200 mg, Twice daily, 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)
Description: Tablets, Oral, 0 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)
Description: Tablets, Oral, 0 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ribavirin (RBV)
Description: Tablets, Oral, 0 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ribavirin (RBV)
Description: Tablets, Oral, 0 mg, Twice daily, 16 weeks